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ABSTRACT
Blood-spinal cord barrier (BSCB) alterations, including capillary rupture, have
been demonstrated in animal models of amyotrophic lateral sclerosis (ALS) and
ALS patients. To date, treatment to restore BSCB in ALS is underexplored. Here,
we evaluated whether intravenous transplantation of human bone marrow CD34+
(hBM34+) cells into symptomatic ALS mice leads to restoration of capillary integrity
in the spinal cord as determined by detection of microhemorrhages. Three different
doses of hBM34+ cells (5 × 104, 5 × 105 or 1 × 106) or media were intravenously
injected into symptomatic G93A SOD1 mice at 13 weeks of age. Microhemorrhages
were determined in the cervical and lumbar spinal cords of mice at 4 weeks posttreatment, as revealed by Perls’ Prussian blue staining for ferric iron. Numerous
microhemorrhages were observed in the gray and white matter of the spinal cords
in media-treated mice, with a greater number of capillary ruptures within the
ventral horn of both segments. In cell-treated mice, microhemorrhage numbers
in the cervical and lumbar spinal cords were inversely related to administered cell
doses. In particular, the pervasive microvascular ruptures determined in the spinal
cords in late symptomatic ALS mice were significantly decreased by the highest cell
dose, suggestive of BSCB repair by grafted hBM34+ cells. The study results provide
translational outcomes supporting transplantation of hBM34+ cells at an optimal dose
as a potential therapeutic strategy for BSCB repair in ALS patients.

brain and spinal cord leading to paralysis and eventual
death within 3-5 years after symptom onset [1, 2]. The
majority of ALS cases (90-95%) are sporadic (SALS)
with unknown cause. Approximately 5-10% of cases
are genetically linked (familial cases, FALS) of which

INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a rapidly
progressing debilitative neurodegenerative disorder
characterized by motor neuron degeneration in the
www.impactjournals.com/oncotarget
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20% have a missense mutation in the Cu/Zn superoxide
dismutase 1 (SOD1) gene [3, 4]. Additional mutations in
the transactive response DNA binding protein (TARDBP;
TDP-43), fused in sarcoma/translocated in liposarcoma
(FUS/TLS), angiogenin (ANG), and chromosome 9 open
reading frame 72 (C90RF72) genes have been identified
in FALS cases (reviewed in [5-9]); some of these
mutations were noted in SALS cases. Despite the genetic
variants, SALS and FALS share clinical and pathological
presentations. The treatment options for ALS are mostly
supportive. The only approved drugs for ALS by the
United States of America Federal Drug Administration
are riluzole [10] and the recently approved Radicava
(edaravone).
ALS is a multifactorial disease with numerous
effectors underlying disease pathogenesis such as
glutamate excitotoxicity, oxidative stress, mitochondrial
dysfunction, impaired axonal transport, aberrant RNA
metabolism, protein aggregations, dysfunctional
autophagy, modified glial cell function, altered
neurotrophic factor levels, immune reactivity, and
neuroinflammation (reviewed in [11-23]). Accumulating
evidence [24-31] has also shown breakdown of the bloodcentral nervous system-barrier (B-CNS-B), i.e. the bloodbrain barrier (BBB) and the blood-spinal cord barrier
(BSCB), potentially representing an additional pathogenic
mechanism identifying ALS as a neurovascular disease
[32]. The essential role of the B-CNS-B is to maintain
homeostasis within the CNS by preventing diffusion of
detrimental factors from the blood circulation to the CNS
[33-35]. The barriers are composed of endothelial cells
and tight junctions that interact with pericytes, astrocytes,
perivascular macrophages and the basal lamina to form
an integrated microvascular unit [33]. Originally, we
demonstrated B-CNS-B impairment in ALS patients
[25] and the G93A SOD1 mouse model of ALS [24,
26]. In the G93A mice, endothelial cell degeneration
and astrocyte end-feet alterations have been observed
before disease onset as well as at different stages of the
disease [24, 26, 28]. Importantly, BSCB alterations were
indicated in SOD1 mutant mice and rats prior to motor
neuron degeneration and neuroinflammation [28, 29, 31],
suggesting vascular damage as an early ALS pathological
event. Moreover. compromised BSCB integrity was
demonstrated by Evans blue dye extravasation into CNS
parenchyma in pre-symptomatic [26] and symptomatic
G93A rodents [29]. Reductions of tight junction proteins
such as zonula occludens 1 (ZO-1), occludin, and
claudin-5 have also been detected in the ventral horn of the
lumbar spinal cord [28, 31] in G93A SOD1 mice at presymptomatic and symptomatic disease stages. However,
decreased levels of tight junction proteins were determined
in G93A SOD1 rats mainly at the symptomatic stages
[29]. Studies using post-mortem human ALS tissues in
several laboratories [25, 27, 28, 36] also support diseaserelated BSCB dysfunction by demonstrating endothelial
www.impactjournals.com/oncotarget

cell degeneration, astrocyte end-feet alterations, and
reduction of tight junction protein expressions. Thus, it
is possible that the initiating pathological trigger for ALS
is a dysfunctional B-CNS-B, allowing detrimental factors
from the systemic circulation to penetrate the CNS and
initiate inflammation fostering motor neuron degeneration
[30, 36].
Microhemorrhages within the CNS parenchyma
are indicative of capillary damage within the B-CNS-B
[23, 29, 36]. These capillary ruptures may be identified
through detection of ferric iron deposits derived from the
blood compartment [29-31, 36, 37]. A significantly higher
number of hemosiderin deposits have been observed in
the ventral horn of the cervical spinal cord of ALS patients
[36] and the ventral horn of the lumbar spinal cord in a
rodent model of ALS [29-31]. However, the distribution
of microhemorrhages within the gray and white matter of
both the cervical and lumbar spinal cord of ALS patients
and rodents has not previously been reported.
Since BSCB dysfunction is a potential contributor to
ALS pathogenesis, restoration of BSCB integrity could be
an important target in treatment development for ALS. We
have recently shown that unmodified human bone marrow
CD34+ (hBM34+) stem cells intravenously transplanted
into symptomatic ALS mice dose-dependently
differentiate into endothelial cells and engraft into the
capillary walls in the cervical and lumbar spinal cords at
4 weeks post-transplantation [38]. Moreover, mice treated
with the highest cell dose demonstrated improvements in
behavioral disease outcomes and motor neuron survival
in addition to reductions of macro- and microgliosis,
maintenance of perivascular end-feet astrocytes, and
reduction of capillary permeability. These study results
may indicate BSCB repair processes after transplantation
of hBM34+ cells into symptomatic ALS mice. However,
it is still unclear if structural and/or functional BSCB
restoration occurred via cell transplantation. Although
we showed that extravasation of Evans blue dye into
the spinal cord was significantly reduced in ALS mice
receiving the high dose of hBM34+ cells [38], functional
BSCB repair needed to be revealed by investigating the
cell transplant effect on spinal cord capillary ruptures.
The aim of this study was to determine whether
intravenous transplantation of hBM34+ cells at different
doses into symptomatic G93A SOD1 mice leads
to restoration of capillary integrity by detection of
microhemorrhages. A specific focus was defining the
distributions of microhemorrhages in the gray and white
matter of the cervical and lumbar spinal cord enlargements
in the cell-treated mice vs. media-treated ALS mice.

RESULTS
The effect of intravenous administration of different
doses of hBM34+ cells into symptomatic G93A SOD1
mice (13 weeks old) on capillary integrity was analyzed
10622
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by detection of microhemorrhages in the cervical and
lumbar spinal cords. Microhemorrhages, as free iron
deposits, were observed in the cervical and lumbar spinal
cords of each animal 4 weeks after cell transplantation.
Quantitative capillary rupture analysis was performed in
the ventral horn, dorsal horn, lateral white matter, anterior
white matter, and posterior white matter regions within
the cervical (C4-C6) and lumbar (L3-L5) spinal cord
enlargements. Of the 31 total G93A SOD1 mice used in
the study, five animals (Group 1 – one, Group 3 – two,
Group 4 – two) were excluded due to premature death at
15-16 weeks of age or death from anesthetic complications
during cell/media administrations.

the white matter in media-treated, low, and mid cell-dose
treated mice, with the exception of the high cell-dose mice.

Microhemorrhages within the lumbar spinal
cords of G93A mice
Similarly to the cervical spinal cords,
microhemorrhages were rarely detected in the control mice
(Figure 2Aa-e), but numerous microhemorrhages were
observed throughout the lumbar spinal cord of the mediatreated mice in all analyzed regions (Figure 2Af-j). The
microhemorrhages varied in size within each animal group.
In media-treated mice, numerous large microhemorrhages
were determined mainly in the ventral horn (Figure 2Af),
dorsal horn (Figure 2Ag), and anterior white matter (Figure
2Ai). Ferric iron deposits were observed in all analyzed
spinal cord regions of the low cell-dose treated mice (Figure
2Ak-o). In mid cell-dose treated mice, microhemorrhages
were detected in the gray matter (Figure 2Ap, q) and
lateral or anterior white matter (Figure 2Ar, s) but not in
the posterior white matter region (Figure 2At). However,
microhemorrhages were identified in the gray matter
(Figure 2Au, v) and lateral white matter (Figure 2Aw) of
high cell-dose treated mice. In the anterior (Figure 2Ax) and
posterior (Figure 2Ay) white matter of these treated mice no
iron deposits were observed.
Significantly (p<0.01) more microhemorrhages
were observed in the lumbar spinal cord of the mediatreated mice compared to the controls (Figure 2B). Celldose dependent decreases in microhemorrhage numbers in
comparison to media-treated mice were determined after
hBM34+ cell transplantation, reaching significance in both
the mid (p<0.05) and high cell-dose (p<0.01) mice.
In the media-treated mice, the percentage of
microhemorrhages within each region of the lumbar spinal
cord decreased as follows: ventral horn (41.0%), dorsal
horn (28.2%), lateral white matter (15.4%), anterior white
matter (10.3%), and posterior white matter (5.1%) (Table
1B). A similar pattern of microhemorrhage distribution
was also seen in the low dose mice. No microhemorrhages
were observed in the posterior white matter of the mid
dose mice or the anterior and posterior white matter of the
high cell-dose mice. Overall, no microhemorrhages were
detected in 33% and 50% of the mid and high dose mice
respectively, while microhemorrhages were observed in
100% of the media and low dose mice. The number of
microhemorrhages within the gray matter was higher vs.
white matter in media-treated and all cell treated mice.

Microhemorrhages within the cervical spinal
cords of G93A mice
Perl’s Prussian blue staining revealed ferric iron
deposits, consequences of microhemorrhages, within the
gray and white matter parenchyma of the cervical spinal
cord in all examined animals to different degrees. While
microhemorrhages were rare in the control mice (Figure 1Aae), numerous microhemorrhages were observed in mediatreated mice in all five evaluated regions (Figure 1Af-j). The
microhemorrhages varied in size within each animal group
with more detected in the lateral and anterior white matter of
media-treated animals. Similarly to media-treated mice, ferric
iron deposits were observed in analyzed spinal cord regions
of the low (Figure 1Ak-o) and mid (Figure 1Ap-t) cell dosetreated mice. However, no microhemorrhages were detected
within the ventral horn (Figure 1Au), dorsal horn (Figure
1Av), or anterior white matter (Figure 1Ax) of the high cell
dose-treated mice. Of note, some small microhemorrhages
were observed in the lateral white matter (Figure 1Aw) and
the posterior white matter (Figure 1Ay) in these mice.
Quantitative analysis of microhemorrhages in the
cervical spinal cords determined a significantly (p<0.05)
higher number of microhemorrhages in the media-treated
mice compared to controls (Figure 1B). Cell-dosedependent decreases in the number of microhemorrhages
were noted after hBM34+ cell transplantation compared
to the media-treated mice, reductions which reached
significance (p<0.05) in the high cell-dose mice. In the
media-treated mice, the percentages of microhemorrhages
decreased across the regions as follows: ventral horn
(35.5%), dorsal horn (22.6%), anterior white matter
(22.6%), lateral white matter (16.1%) and posterior
white matter (3.2%) (Table 1A). A similar pattern of
microhemorrhage distribution was also seen in the low
and mid dose-treated mice, however, only a few iron
deposits were detected in ALS mice treated with the
high cell-dose. Importantly, no microhemorrhages were
detected in 50% of the high cell-dose treated mice,
although microhemorrhages were observed in 100% of
the media, low, and mid cell-dose mice. The number of
microhemorrhages within the gray matter was greater vs.
www.impactjournals.com/oncotarget

Topographic distribution of microhemorrhages
within the spinal cords of G93A mice
Topographic distribution of microhemorrhages in the
cervical and lumbar spinal cords of media-treated and celltreated mice was analyzed by visual detection of the gray
and white matter tissues accordingly to the mouse spinal
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cord atlas [39] and the ascending/descending pathways as
described [40]. Microhemorrhage locations in the C4-C6
and L3-L5 spinal cord enlargements were mapped onto
each analyzed spinal cord segment. Figure 3 presents
overall microhemorrhage distribution in the gray and white
matter for each animal group at C4 and L4 segments.
In the cervical spinal cords of control mice, a few
microhemorrhages were detected in the gray and white
matter (Figure 3A). Within the ventral horn of mediatreated mice, the majority of microhemorrhages were
noted in the ventral horn of lamina 7Sp and some were
observed in lamina 9Sp (Figure 3B). The number of
microhemorrhages decreased within these regions of
the cervical spinal cord in a cell-dose dependent fashion
after hBM34+ cell transplantation. However, numerous
iron deposits were still identified in low and mid celldose treated mice, mainly at level of lamina 7Sp (Figure
3C, 3D). No microhemorrhages were determined at
level of lamina 9Sp and only a few iron deposits were
observed at lamina 7Sp in mice receiving the high celldose (Figure 3E).
Microhemorrhages within the cervical dorsal horn
of media-treated mice were primarily localized in the

3Sp, 4Sp, and 5Sp laminas (Figure 3B). Microhemorrhage
numbers decreased with escalating cell doses (Figure 3C,
3D). In high cell-dose treated mice no microhemorrhages
were observed within the dorsal horn (Figure 3E). In
the cervical white matter of the media-treated mice,
many microhemorrhages were determined in the lateral
and anterior white matter (Figure 3B) corresponding to
areas of ascending and descending pathways, such as
the spinothalamic and reticulospinal tracts. Fewer iron
deposits were found in low and mid cell-dose treated mice
(Figure 3C, 3D). No microhemorrhages were observed in
the high cell-dose mice within the anterior white matter
area related to the descending pathways (Figure 3E).
In contrast to the cervical spinal cord, the topographic
distribution of the microhemorrhages within the ventral
horn of the lumbar spinal cord in media-treated mice
revealed similar locations in laminas 7Sp and 9Sp (Figure
3B). A dose-dependent decrease in microhemorrhages
was evident in mice treated with low and mid cell-doses
(Figure 3C, 3D). Only a few microhemorrhages were
present at lamina 9Sp in the high-dose mice (Figure
3E). In the dorsal horn of the lumbar spinal cord,
microhemorrhages were found throughout laminas 1Sp-

Figure 1: Distribution of microhemorrhages within the cervical (C4-C6) spinal cord of G93A mice after cell transplantation.

Tissue sections from the C4-C6 enlargement segment of the cervical spinal cord of 17 week old G93A mice were stained with Perl’s Prussian blue
to reveal ferric iron deposits as markers of microhemorrhages (blue). The tissue was counterstained with nuclear fast red (nuclei - red, cytoplasm
- pink). (A) Numerous microhemorrhages (^) were detected within the parenchyma of the ventral and dorsal horns, lateral, anterior, and posterior
white matter of the cervical spinal cord of ALS mice receiving media (f-j), low (k-o), or mid (p-t) cell dose. No microhemorrhages were seen in
ventral or dorsal horns (u, v) and anterior white matter (x) of the high cell-dose mice. However, some small microhemorrhages were observed in
the lateral white matter (w) and the posterior white matter (y) in these mice. A small iron deposit was detected in the ventral horn (a) of control
mice. Yet, microhemorrhages were not detected in dorsal horn (b), or white matter (c-e) in these animals. In 50% of the high cell-dose mice, no
microhemorrhages were observed. Scale bar is 50 μm. (B) Quantitative analysis of microhemorrhage distribution in the cervical spinal cord of the
control and G93A mice. Media-treated mice showed a significantly (*p<0.05) higher number of microhemorrhages vs. controls. Microhemorrhages
decreased inversely with cell dose, reaching significance with high cell-dose vs. media-treated mice (*p<0.05).
www.impactjournals.com/oncotarget
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6Sp in the media-treated mice (Figure 3B). The overall
cell-dose dependent decrease of microhemorrhages in the
lumbar spinal cord mirrored patterning of iron deposits
in the cervical dorsal horn (Figure 3C-3E). Only a small
number of microhemorrhages were found within laminas
2Sp and 3Sp of the high cell-dose treated mice (Figure
3E). Within the lumbar white matter of the media-treated
mice, noted microhemorrhages corresponded with the
locations of ascending (spinocerebellar and spinothalamic)
and descending (corticospinal and reticulospinal) pathways
(Figure 3B). In the lumbar white matter of the ALS mice
treated with low or mid cell doses, a few iron deposits
were determined, mainly within the lateral white matter
corresponding to ascending pathways (Figure 3C, 3D). In
high cell-dose treated mice, microhemorrhages were only
observed in the area of the lateral spiny nucleus (Figure 3E).

into symptomatic G93A SOD1 mice was explored to
determine the presence of microhemorrhages 4 weeks
post-treatment, as an indicator of putative BSCB
repair. The major study findings were: (1) widespread
distribution of microhemorrhages within the gray and
white matter parenchyma of the cervical and lumbar
spinal cord of late symptomatic media-treated G93A
mice; (2) more microhemorrhages in the gray matter vs.
white matter of the spinal cords in media-treated ALS
mice; (3) higher microhemorrhage occurrence in the
lumbar vs. the cervical spinal cord in media-treated ALS
mice; (4) significant decrease of microhemorrhages in
the cervical spinal cords of high cell-dose G93A mice;
and (5) significant decrease of microhemorrhages in the
lumbar spinal cords of mid and high cell-dose G93A
mice. Pervasive microvascular ruptures determined in
the gray and white matter of the cervical and lumbar
spinal cords in late symptomatic ALS mice are important
findings. This vascular pathology in ALS may have
implication for disease pathogenesis and highlights the
microvasculature as a novel therapeutic target. Here,

DISCUSSION
In the present study, the effect of intravenously
administering a low, mid or high dose of hBM34+ cells

Figure 2: Distribution of microhemorrhages within the lumbar (L3-L5) spinal cord of G93A mice after cell
transplantation. Tissue sections from the L3-L5 enlargement segment of the lumbar spinal cord of 17 week old G93A mice were stained
with Perl’s Prussian blue to reveal ferric iron deposits as markers of microhemorrhages (blue). The tissue was counterstained with nuclear
fast red (nuclei - red, cytoplasm - pink). (A) Distribution of microhemorrhages (^) in the gray and white matter of the lumbar spinal cord
was similar to cervical spinal cord. Although no capillary ruptures were determined in gray (a, b) or white (c-e) matter of control mice,
numerous microhemorrhages were observed in media-treated (f-j) and low cell-dose mice (k-o). In mid cell-dose treated mice, iron deposits
were detected in gray matter (p, q) and lateral/anterior white matter (r, s). No microhemorrhages in posterior white matter of mid (t) or high
(y) cell-dose mice or anterior white matter of high dose mice (x) were determined. However, some capillary ruptures were noted in gray
matter (u, v) and lateral white matter (w). No microhemorrhages were detected in 33.3% of mid cell-dose and 50% of high cell-dose mice.
Scale bar is 50 μm. (B) Quantitative analysis of microhemorrhage distribution in the lumbar spinal cord of the control and G93A mice.
Media-treated mice demonstrated a significantly (**p<0.01) higher number of microhemorrhages vs. controls. Microhemorrhages decreased
inversely with cell dose, reaching significance with mid (*p<0.05) and high (**p<0.01) cell-doses vs. media-treated mice.
www.impactjournals.com/oncotarget
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Table 1: Distribution of microhemorrhages in the cervical and lumbar spinal cords
Animal group

Average number of
microhemorrhages
± S.E.M.

Number/percentage of microhemorrhages by spinal cord region

Ventral horn

Dorsal horn

Lateral white
matter

Anterior
white matter

Posterior
white matter

A. Cervical spinal cord
Control

0.67 ± 0.33

2/50.0

0/0.0

1/25.0

1/25.0

0/0.0

Media

5.17 ± 1.19

11/35.5

7/22.6

5/16.1

7/22.6

1/3.2

Low dose

3.83 ± 0.98

7/30.5

5/21.7

5/21.7

5/21.7

1/4.4

Mid dose

3.17 ± 0.98

6/31.6

5/26.3

2/10.5

4/21.1

2/10.5

High dose

1.00 ± 0.63

2/33.3

0/0.0

1/16.7

0/0.0

3/50.0

B. Lumbar spinal cord
Control

0.50 ± 0.34

1/33.4

1/33.3

0/0.0

1/33.3

0/0.0

Media

6.50 ± 0.92

16/41.0

11/28.2

6/15.4

4/10.3

2/5.1

Low dose

3.67 ± 1.31

10/45.5

6/27.3

3/13.6

2/9.1

1/4.5

Mid dose

2.00 ± 1.06

4/33.3

3/25.0

3/25.0

2/16.7

0/0.0

High dose

1.17 ± 0.79

3/42.8

2/28.6

2/28.6

0/0.0

0/0.0

In the cervical (A) and lumbar (B) spinal cords of media-treated mice, higher numbers of microhemorrhages were
determined in the ventral and dorsal horns compared to white matter areas. Cell-transplanted mice demonstrated a
similar distribution pattern to media-treated mice with a substantial reduction of microhemorrhages in the spinal
cords of ALS mice receiving the high cell-dose. No microhemorrhages were detected in cervical dorsal horn,
cervical anterior white matter, lumbar anterior white matter, or lumbar posterior white matter in high cell-dose
mice.
we are the first to demonstrate, from a translational
viewpoint, that administration of hematopoietic stem
cells derived from bone marrow at symptomatic disease
stage prevents capillary rupture, potentially leading to
BSCB repair in ALS. Although the high dose of 1 × 106
cells provided the most beneficial effect on restoration
of capillary integrity in the cervical and lumbar spinal
cords at 4 weeks post-transplantation, the mid (1 × 105)
cell dose also demonstrated a significant decrease of
microhemorrhages in the lumbar spinal cord, suggesting
a range of therapeutic cell doses for hBM34+ cells to be
effective in ALS. These data support our previous study
results showing that transplantation of hBM34+ cells into
symptomatic ALS mice, specifically with the higher celldoses, reduced Evans blue extravasation into spinal cord
parenchyma and delayed disease progression [38]. Thus,
reduction of microhemorrhages in the spinal cords of
symptomatic ALS mice via administration of mainly the
higher doses of hBM34+ cells confirms potential vascular
repair towards BSCB restoration in ALS.
Numerous reports have demonstrated structural and
functional impairment of B-CNS-B in ALS patients [25,
27, 28, 36] and in animal models of disease [24, 26, 2831] including vascular leakage or even microhemorrhages.
www.impactjournals.com/oncotarget

Results of our present study showed numerous
microhemorrhages within the parenchyma of the lumbar
spinal cord in late symptomatic ALS mice, supporting
previous findings on capillary ruptures in this spinal cord
segment in a rodent model of ALS [28-31]. However,
to our knowledge, our present study is the first to
demonstrate microhemorrhages within the gray and white
matter of the cervical spinal cord of symptomatic ALS
mice. Of note, microhemorrhages have been previously
reported in post-mortem cervical spinal cords from ALS
patients [36]. However, no microbleeds were detected in
twelve ALS patients with disease duration averaging 14.3
months using the T2-weighted whole-brain imaging by 7
Tesla magnetic resonance imaging (MRI) [41], possibly
due to undetectable microhemorrhages at this early stage
of the disease. A lack of detectable capillary ruptures in
ALS patient’s brains does not preclude microhemorrhages
in the spinal cords of ALS patients [42], which likely
present as subtle pathological microvessel alterations.
Although our quantitative data showed that both
the cervical and lumbar spinal cords of media-treated
symptomatic mice showed microhemorrhages, the lumbar
spinal cord tended to have more microhemorrhages than
the cervical spinal cord in these mice. This difference in
10626
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media-treated mice at 17 weeks of age was primarily due
to a greater number of gray matter (ventral + dorsal horns)
microhemorrhages in the lumbar (total number: 27) than

in the cervical (total: 18) spinal cord. Our study results
demonstrating a higher incidence of microhemorrhages
in the ventral horn vs. the dorsal horn in the lumbar

Figure 3: Schematic depiction of microhemorrhage distribution within the spinal cord of G93A mice after cell
transplantation. The locations of microhemorrhages (*) within the C4-C6 (left) and L3-L5 (right) segments of the spinal cord of control
(A), and media-treated (B), low (C), mid (D), and high (E) cell-dose G93A mice are topographically mapped on the C4 and L4 segments
accordingly to the mouse spinal cord atlas. In media-treated mice (B), numerous microhemorrhages were determined in the gray matter
of the cervical and lumbar spinal cords. In white matter, microhemorrhages localized to ascending and descending pathways in cervical
and lumbar spinal cords. Microhemorrhages decreased in gray matter of mice inversely with cell dose (C-E) with the greatest reduction
observed in cervical and lumbar spinal cords of high cell-dose mice. In white matter, dose-dependent decrease of microhemorrhages (C-E)
was determined only in cervical descending pathway and lumbar lateral spiny nuclei of high cell-dose mice. VH: ventral horn, DH: dorsal
horn, Lwm: lateral white matter, Awm: anterior white matter, Pwm: posterior white matter. Scale bar in spinal cord section is 5mm.
www.impactjournals.com/oncotarget
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segments of media-treated symptomatic ALS mice,
potentially leading to motor neuron loss, are supported by
previously published data [31] showing significantly more
hemosiderin deposits in the anterior horn than in posterior
horn of the lumbar spinal cord of different SOD1 mutant
mice even at pre-symptomatic disease stage. Similarly,
deposition of hemosiderin was observed in the ventral
horn of the lumbar spinal cords around blood vessels and
at close proximity of motor neurons in about 50% of G93A
SOD1 rats at pre-symptomatic or symptomatic disease
stages [29]. However, the authors showed that Evans
blue dye extravasation was significantly increased in the
brainstem and spinal cord of ALS rats only at symptomatic
stage. This discrepancy between hemosiderin deposits and
Evans blue capillary permeability in the spinal cords of
rats modeling ALS needs more comprehensive evaluation
in relation to disease progression.
Our other study finding is that the number of white
matter (lateral + anterior + posterior) microhemorrhages
was similar between the cervical (total number: 13)
and lumbar (total number: 12) spinal cord segments in
late symptomatic ALS mice. Interestingly, it has been
shown that pre-symptomatic G93A mice demonstrated
hemosiderin deposits in the lateral, anterior, and posterior
funiculi with most detected in the lateral funiculus
[31]. Unfortunately, the authors did not investigate the
possibility of capillary ruptures in the cervical spinal cords
of these mice.
Microhemorrhage, or capillary rupture, leads to
blood-borne compounds exiting the capillary lumen into
the surrounding CNS tissue parenchyma. Capillary
ruptures, leading to the extravasation of erythrocytes, have
been observed in various CNS disorders such as multiple
sclerosis [37], cerebral ischemia [43] and post-traumatic
epilepsy [44]. Extravasated red blood cells release free
iron, a product of hemoglobin degradation, considered
toxic to neurons, and this free iron might promote neuronal
cell death through generation of free radicals [45]. The
toxic effect of hemosiderin has been shown to contribute
to early motor neuron dysfunction via an iron-dependent
mechanism in ALS mice, indicating a loss of BSCB
integrity [30]. Our study takes advantage of the fact that
ferric iron can be detected by Prussian blue staining and
the ferric iron-containing complex of polysaccharides and
proteins from the metabolism of erythrocytes and other
blood-borne components, known as hemosiderin, can be
found in the surrounding parenchyma following capillary
rupture. Other toxic entities also exist in the blood,
including thrombin and fibrinogen (metabolized to fibrin),
which can have inflammatory, angiogenic and neurotoxic
effects on nearby cells by entering the CNS parenchyma
following capillary rupture and contribute to neurovascular
damage in mouse models of Alzheimer’s disease [46,
47]. Our previous studies have shown perivascular fibrin
deposits in the spinal cords of an ALS mouse model
[26] and ALS patients [25], supporting the possibility
www.impactjournals.com/oncotarget

of toxic moieties within the CNS parenchyma due to
BSCB breakdown. Fibrin and thrombin accumulations
within motor neurons have also been detected following
BSCB disruption in mice with a deficiency of pericytes,
an important cellular component of the BSCB [48].
Additionally, studies have demonstrated the presence of
immunoglobulin G (IgG) and C3/C4 complement within
the spinal cord parenchyma of ALS animal models [26,
29] and ALS patients [30, 49, 50], substances which may
promote motor neuron dysfunction and cell death. Thus,
capillary rupture, detected prior to disease symptoms,
worsened during disease progression as we demonstrated
in the current study; widespread microhemorrhages in the
gray and white matter of the cervical and lumbar spinal
cords were determined in late symptomatic G93A mice.
In the present study, the effect of intravenously
administered hBM34+ cells at low (5 × 104), mid (5 × 105)
or high (1 × 106) dose into symptomatic G93A SOD1 mice
on reducing capillary rupture was examined by detection
of microhemorrhages in the spinal cords at 4 weeks posttransplantation. A significant decrease in the number of
microhemorrhages was observed in both the cervical and
lumbar spinal cords of ALS mice mainly receiving the
high cell dose compared to the media-treated mice. These
results were consistent with those of our previous study
[38] showing a substantial decrease of Evans blue dye
extravasation into spinal cord parenchyma in symptomatic
ALS mice after receiving the same high dose of hBM34+
cells. This effect might be, as the authors noted [38], due
to differentiation of transplanted cells into endothelial cells
and subsequent differentiated endothelial cell engraftment
within numerous spinal cord capillaries, improving BSCB
integrity by likely replacement of damaged endothelial
cells. However, transplanted stem cells could additionally
provide endogenous repair of endothelial cells in ALS by
secretion of specific angiogenic factors. Recently, Ropper et
al. [51] showed that transplantation of human bone marrow
mesenchymal stromal stem cells (hMSCs) embedded
within a PLGA scaffold into injured rat spinal cord exert
beneficial effects on cell engraftment, hindlimb locomotion,
and neurogenesis. The authors also provided evidence that
the scaffolded hMSCs secreted laminin α2 and α5 along
capillary structures proximal to the implantation site in
post-injured rat spinal cord, promoting angiogenesis.
Since laminin is a major component of the basal lamina
(i.e. basement membrane), this extracellular matrix
protein has a vital role for the maintenance of B-CNS-B
integrity. We have demonstrated [26] a decrease of laminin
immunoexpression in capillaries of the cervical/lumbar
spinal cords in ALS mice at early and late stage disease,
indicating basement membrane disruption. Presently, we
are investigating laminin presence in capillary basement
membrane of the spinal cords of ALS mice treated with
hBM34+ cells and study results will be reported in an
upcoming paper.
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Moreover, we reported [38] decreases of macro- and
microgliosis, including enhancement of perivascular astrocyte
end-feet, in the spinal cords of mainly high cell-dose treated
ALS mice at 4 weeks post-transplantation, concurrent with
reductions of microhemorrhages in ALS mice observed in
the current study. Specifically, we noted re-establishment of
astrocyte end-feet capillary coverage, potentially lessening
BSCB permeability and preventing capillary rupture.
Since a single intravenously administrated hBM34+
cell dose into early symptomatic ALS mice showed benefit
towards BSCB repair, repeated cell transplantations might
better encourage ongoing reparative processes of the
damaged barrier. ALS-like disease symptoms quickly
progress in G93A SOD1 mice and mouse lifespan is
limited to 6-7 weeks after initial symptoms in this disease
model. The prevalence and severity of capillary barrier
damage, predominantly by endothelial cell degeneration,
in the brain and spinal cords of ALS mice significantly
increases during disease progression [24, 26]. Thus,
repeated cell administrations (potentially weekly) might
substantially contribute to ongoing replacement or
endogenous repair of damaged endothelial cells over the
course of the disease. Also, repeated smaller cell doses
might be a better therapeutic approach for B-CNS-B repair
in ALS. This study is currently underway.
Additionally, our examination of the spinal
cords in control mice revealed the presence of a few
microhemorrhages in the cervical and lumbar spinal
cords, predominantly in the ventral horn, lateral and
anterior white matter. While microhemorrhages in the
control mice were rare, our finding agrees with other
reports of rare microhemorrhages detected in the lumbar
spinal cords of control mice or cervical spinal cords of
non-neurodegenerative disease controls [30, 31, 36].
Potentially, uncontrolled fluid pressure during animal
perfusion might be the cause of capillary rupture in these
animals. In our study, all mice were perfused transcardially
under pressure controlled delivery of phosphate buffer
(PB) at 80-85mm Hg, while the normal arterial diastolic
blood pressure of a mouse is approximately 102 mm Hg
[52]. This technique avoids perfusion-related capillary
rupture and has proven effective in our studies [24,
26, 38]. Alternatively, since angiogenesis involves the
proliferation and migration of endothelial cells from
already developed vessels for the sprouting of new vessels
[53], newly formed vessels could have compromised
integrity leading to capillary leakage. This possibility may
also be true in animal models of ALS, due to continuous
renewal of the endothelial cell layer within the capillary
lumen. The presence of multiple layers of endothelial
cells has been detected within capillaries of the brain and
spinal cord in ALS mice, but not in controls, suggesting
that a continuous renewal process may be responsible
for replacement of damaged endothelial cells in ALS
[24]. Interestingly, we showed a significant increase of
microvascular density in the ventral lumbar spinal cord in
www.impactjournals.com/oncotarget

sporadic ALS patients, a potential sign of compensatory
neovascularization in regards to damaged capillaries in
areas of motor neuron degeneration [25]. The new vessels
may only partially support functional B-CNS-B properties,
showing capillary leakage. Ongoing angiogenesis and
increased vascular density has been observed in postmortem tissue from patients with Alzheimer’s disease
[54], Parkinson’s disease and progressive supranuclear
palsy [55], suggesting that microvascular turnover may
contribute to the occurrence of B-CNS-B dysfunction in
these disorders. However, additional investigations are
needed to confirm neovascularization in ALS.
Finally, our study results demonstrated widespread
microhemorrhages in the spinal cords of late symptomatic
ALS mice consistent with impairment of the motor neuron
pathways at several levels. Microhemorrhages detected
within the 9Sp lamina could directly affect cell bodies of
motor neurons, while capillary ruptures within 7Sp raise
the possibility of impaired interneuron communications
between the dorsal sensory neurons and the ventral motor
neurons. Microhemorrhages within lamina 1Sp-6Sp could
degrade sensory input. Microhemorrhages within the
white matter of the spinal cord could result in the toxic
entities, which might interact with the myelin of the axons
comprising the ascending and descending spinal cord
pathways. Changes in myelin composition as well as myelin
disorganization at the electron microscopy level have been
reported in both pre-symptomatic and symptomatic G93A
rats [56]. Also, degeneration of oligodendrocytes in the
gray and white matter of the spinal cord has also been
observed in both ALS patients and animal models [57,
58]. Widespread degeneration of the white matter tracts in
G93A mice and ALS patients has also been reported [5963]. Our recently published study [38] demonstrated severe
astrogliosis in the reticulospinal and spinothalamic tracts of
symptomatic G93A mice. However, some limitations of our
current study relate to determination of lifespan and BBB
repair in the brains of post-transplanted ALS mice.
In summary, pervasive microvascular ruptures
determined in the gray and white matter of the cervical
and lumbar spinal cords in late symptomatic ALS mice
may have implications for disease pathogenesis and
identify the microvasculature as a novel therapeutic target.
The intravenous administration of hBM34+ cells into
symptomatic ALS mice showed dose-dependent reductions
of microhemorrhages in the cervical and lumbar spinal
cords. These results support efficacy of hBM34+ cell
transplantation at optimal cell dose as a potential future
therapeutic strategy for repair of the BSCB in ALS.

MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with
the ethical standards and according to the Declaration of
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Helsinki and according to national and international
guidelines and has been approved by the Institutional
Animal Care and Use Committee at USF and conducted
in compliance with the NIH’s Guide for the Care and Use
of Laboratory Animals.
The mice were maintained on a 12:12 hr. dark:light
cycle commencing at 6 PM and were housed in a
temperature-controlled room at 23°C. Mice had access
to food and water ad libitum. Thirty-one transgenic male
B6SJL-Tg (SOD1*G93A)1Gur/J mice, over-expressing
human SOD1 carrying the Gly93→Ala mutation (G93A
SOD1), and six non-carrier mutant SOD1 gene mice from
the background strain (controls) at 7 weeks of age were
received from Jackson Laboratories (Bar Harbor, ME,
USA). At approximately 13 weeks of age, when initial
disease symptoms such as hindlimb tremor and reduction
in body weight appeared, the G93A mice were randomly
assigned to one of four groups receiving hBM34+ cells or
media: Group 1 - hBM34+ (5 × 104 cells/mouse, low dose,
n=7), Group 2 - hBM34+ (5 × 105 cells/mouse, mid dose,
n=7), Group 3 - hBM34+ (1 × 106 cells/mouse, n=9), and
Group 4- media (Dulbecco’s Phosphate buffered saline
[DPBS], n=8). The control mouse group (Group 5, n=6)
did not receive either cell transplant or media injection.

ml/kg body weight) and perfused transcardially with 0.1
M PB (pH 7.2) followed by 4% paraformaldehyde (PFA)
in PB solution under pressure controlled fluid delivery at
80-85 mm Hg to avoid capillary rupture. The spinal cord
was then carefully removed and post-fixed in 4% PFA.
The cervical and lumbar spinal cord segments were
dissected and then cryoprotected in 20% sucrose in 0.1 M
PB overnight. Thirty micron coronal sections were cut on
a cryostat and thaw-mounted onto slides at 150 micron
intervals within the cervical and lumbar cords (i.e. every
5th section). Slides were stored at -20°C until used for
staining of microhemorrhages.

Microhemorrhage staining and analysis
Perls’ Prussian blue staining was performed on
the cervical and lumbar spinal cords from each animal
to identify the presence of ferric iron (Fe3+) within the
parenchyma as an indicator of microhemorrhages. The
slides were thawed and hydrated in distilled water for
2 minutes, followed by transfer to 1:1 solution of 10%
potassium ferrocyanide (Sigma-Aldrich) and 20% HCl for
20 minutes. After rinsing with distilled water, the slides
were counterstained by nuclear-fast red (Sigma-Aldrich)
solution for 5 minutes. Slides were then washed in
distilled water for 5 minutes and dehydrated in increasing
concentrations of ethanol (70%, 80%, 90%, 95%, and
100%) followed by xylene (2 × 3 minutes), and afterwards
coverslipped with PermountTM (Sigma-Aldrich).
Microhemorrhages were observed throughout the
cervical and lumbar spinal cord parenchyma using an
Olympus BX40 microscope with a SPOT RT3 digital
camera (Diagnostic Instruments Inc., Stirling Heights, MI,
USA) under bright field illumination at 20X magnification.
Both the left and right sides of every 5th spinal cord section
(150 μm apart) were examined. The number and location
of microhemorrhages within the cervical and lumbar
spinal cord enlargements [38, 65] were recorded. The
cervical enlargement including C4-C6 segments (1420 sections/mouse/group) and the lumbar enlargement
including L3-L5 segments (10-18 sections/mouse/group)
were examined. Within these segmental regions, the gray
matter was distinguished from the white matter by the
nuclear-fast red counterstain and further defined as the
dorsal or ventral horn based on location above or below,
respectively, a line perpendicular to the midline passing
through the central canal. In the cervical enlargement, the
white matter was characterized as anterior (0-0.3 mm from
anterior section edge, 0-1.0 mm from midline), posterior
(0-0.6 mm from posterior section edge, 0-0.3 mm from
midline), or lateral (0-0.4 mm from lateral section edge,
0.2-1.1 mm from posterior section edge). The white
matter lumbar enlargement was characterized as follows:
anterior (0-0.3 mm from anterior section edge, 0-1.0 mm
from midline), posterior (0-0.6 mm from posterior section
edge, 0-0.2 mm from midline), and lateral (0-0.3 mm from

Cell preparation
Cryopreserved hBM34+ cells (All Cells, Alameda,
CA, USA) were thawed rapidly at 37°C and transferred
into a centrifuge tube containing 10 ml of DPBS (pH
7.4; Mediatech, Inc., Manassas, VA, USA). The cells
were centrifuged at 200 × g for 10 minutes (room
temperature) and the supernatant discarded. Cell viability
was determined using the 0.4% trypan blue dye (SigmaAldrich, St. Louis, MO, USA) exclusion method. The cell
concentrations were then adjusted with DPBS to obtain the
required cell doses at 200μl/animal.

Cell transplant
The G93A mice in Groups 1-3 received 5 × 104,
5 × 105 or 1 × 106 hBM34+ cells in 200 μl of DPBS,
respectively, via the jugular vein over a 3-5 minute period
under isoflurane anesthesia (2-5% at 2L O2/min) as we
previously described [38, 64]. The media-treated mice in
Group 4 received 200 μl of DPBS. Animals in Groups 1-4
received 10 mg/kg (ip) cyclosporine A (Novartis, New
York, NY, USA) daily from the time of transplant until
sacrifice.

Perfusion and tissue preparation
All cell-treated, media-treated, and control mice
were sacrificed at 17 weeks of age (4 weeks after
initial treatment at symptomatic disease stage) for
microhemorrhage analyses in the cervical and lumbar
spinal cords. Mice were sacrificed using Euthasol® (0.22
www.impactjournals.com/oncotarget
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lateral section edge, 0.3-1.2 mm from posterior section
edge). The microhemorrhages were topographically
mapped for each mouse accordingly to the mouse spinal
cord atlas in Watson et al [53]. Additionally, white matter
microhemorrhages were further defined by the ascending
and descending spinal cord pathways outlined in Watson
& Harrison [52].
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